A novel PET tracer 18F-deoxy-thiamine: synthesis, metabolic kinetics, and evaluation on cerebral thiamine metabolism status
EJNMMI Research volume 10, Article number: 126 (2020)
Some neuropsychological diseases are associated with abnormal thiamine metabolism, including Korsakoff–Wernicke syndrome and Alzheimer’s disease. However, in vivo detection of the status of brain thiamine metabolism is still unavailable and needs to be developed.
A novel PET tracer of 18F-deoxy-thiamine was synthesized using an automated module via a two-step route. The main quality control parameters, such as specific activity and radiochemical purity, were evaluated by high-performance liquid chromatography (HPLC). Radiochemical concentration was determined by radioactivity calibrator. Metabolic kinetics and the level of 18F-deoxy-thiamine in brains of mice and marmosets were studied by micro-positron emission tomography/computed tomography (PET/CT). In vivo stability, renal excretion rate, and biodistribution of 18F-deoxy-thiamine in the mice were assayed using HPLC and γ-counter, respectively. Also, the correlation between the retention of cerebral 18F-deoxy-thiamine in 60 min after injection as represented by the area under the curve (AUC) and blood thiamine levels was investigated.
The 18F-deoxy-thiamine was stable both in vitro and in vivo. The uptake and clearance of 18F-deoxy-thiamine were quick in the mice. It reached the max standard uptake value (SUVmax) of 4.61 ± 0.53 in the liver within 1 min, 18.67 ± 7.04 in the kidney within half a minute. The SUV dropped to 0.72 ± 0.05 and 0.77 ± 0.35 after 60 min of injection in the liver and kidney, respectively. After injection, kidney, liver, and pancreas exhibited high accumulation level of 18F-deoxy-thiamine, while brain, muscle, fat, and gonad showed low accumulation concentration, consistent with previous reports on thiamine distribution in mice. Within 90 min after injection, the level of 18F-deoxy-thiamine in the brain of C57BL/6 mice with thiamine deficiency (TD) was 1.9 times higher than that in control mice, and was 3.1 times higher in ICR mice with TD than that in control mice. The AUC of the tracer in the brain of marmosets within 60 min was 29.33 ± 5.15 and negatively correlated with blood thiamine diphosphate levels (r = − 0.985, p = 0.015).
The 18F-deoxy-thiamine meets the requirements for ideal PET tracer for in vivo detecting the status of cerebral thiamine metabolism.
Thiamine, also named vitamin B1, is an essential nutrient that can be acquired only via diet. After being absorbed from gastrointestinal tract, thiamine is delivered to all organs and tissues and converted into bioactive thiamine diphosphate (TDP) . Thiamine deficiency (TD) is associated with some neuropsychological diseases, such as Wernicke–Korsakoff syndrome, Alzheimer’s disease (AD), beriberi, Leigh syndrome, and so forth, and results in lactic acidosis, mitochondrial dysfunction, and energy deficits in brain, muscle, and heart, causing a broad range of clinical manifestations, such as anorexia, agitation, diminished tendon reflexes, ataxia, disturbance of consciousness, muscle pain, and heart failure. [2,3,4].
Glucose is the predominant substrate of brain energy metabolism and plays a pivotal role in maintaining cerebral function , which makes the brain vulnerable to glucose dysmetabolism. TDP is the common coenzyme of the three key enzymes in glucose catabolism: pyruvate dehydrogenase and α-ketoglutarate dehydrogenase in the Krebs cycle that is responsible for producing ATP in mitochondria, and transketolase in pentose phosphate pathway that generates antioxidants and the substrates of biosynthesizing DNA, RNA, and fatty acid in cytosol . Therefore, the brain also is susceptible to TD by disturbing glucose metabolism [2, 7,8,9,10,11,12]
However, in vivo detection of cerebral thiamine metabolism status is still unavailable. In this study, a novel radiotracer of positron emission topography (PET)—18F-deoxy-thiamine—was designed and synthesized (Fig. 1). The metabolic kinetics and retention of 18F-deoxy-thiamine in the brains of animals were studied.
Materials and methods
All reagents were purchased from TCI Development Co., Ltd (Shanghai) and J & K Scientific (Beijing, China) unless otherwise indicated. Thin layer chromatography (TLC) was performed with silica gel layers, and compounds were visualized under UV light. The 1H NMR (300 MHz) spectra of all compounds were acquired on an Advance (Bruker) spectrometer. Chemical shifts (δ) for the proton resonance were reported in parts per million (ppm) downfield from TMS (δ = 0). The identification and purity of precursors as well as cold standard sample (19F-deoxy-thiamine) were determined by a LC–MS instrument (1200/6120, Agilent Technologies Inc.) with a C18 column (4.6 * 150 mm, 5 uM; VP-ODS, Shimadzu) at 0.5 ml per minute (ml/min) flow rate. The mobile phase consisted of 60% methanol and 40% H2O containing millesimal formic acid.
18F ions were obtained from a cyclotron (Cyclone 18 Twin, IBA, Belgium), situated at the Molecular Imaging institute, Jiangsu Huayi Technology Co., Ltd., by the nuclear reaction [18O(p,n)18F]. For automatic synthesis of 18F-deoxy-thiamine, we used a remote-controlled radiolabeling module (RNplus, Synthra) with slight modifications and created the sequence program, based on manual trials. The scheme of modified RNplus module is presented in Additional file 1: Figure 1. We used six reagent supply vials (A1–A5, B1) at the upper part and two reaction vials (vial I and vial II) at the bottom part.
Analytical HPLC (1260, Agilent Technologies Inc.) with the same type of column mentioned above was employed for 18F-deoxy-thiamine characterization and identification. The signal acquisition system consisted of a UV detector (254 nm) and a radio-detector (1IINaI/PMT, Lablogic, USA) in series. The flow rate was 0.8 ml/min, and the mobile phase consisted of methanol and H2O containing 0.05% triethylamine and 50 mM ammonium acetate. The percentage of methanol/H2O changed with running time: 0–15 min (mins), 15%/85%; 15–25 min, methanol increasing to 100% while H2O decreasing to 0%; 25–30 min, methanol 100%.
A micro-PET/CT equipment (Inveon; Siemens Co., USA) was used for detecting the levels of 18F-deoxy-thiamine in the organs of mice and marmosets. During micro-PET/CT scanning, the body temperature of animals was maintained at 37 °C using a heat pad.
C57BL/6 and Institute of Cancer Research (ICR) mice (obtained from the SLAC Laboratory Animal Company, China) were housed in a controlled environment at temperature of 20–26 °C and humidity of 40–70% with free access to food and water. The marmosets were supplied by Jiuting Non-human Primate Facility, Chinese Academy of Sciences, Shanghai. Four marmosets aged 3.1–10.8 years old were employed for micro-PET/CT scanning (M1: 3.1 year, female; M2: 3.5 year, male; M3: 5.4 year, female; M4: 10.8 year, male). At the day of experiment, the marmosets were fetched from the facility and were sent back when the scanning finished.
All animal care and experimental procedures were carried out according to the guidelines of the Animal Care Committee of Fudan University. This study was approved by Medical Experimental Animal Administrative Committee of Fudan University, and the committee on medical ethics of Zhongshan Hospital, Fudan University.
Synthesis of cold standard sample of 18F-deoxy-thiamine as well as precursors (5) and (6).
We synthesized cold standard sample of 18F-deoxy-thiamine as well as precursors (5) and (6) according to the work of Cline JK, et al. , with minor modifications (Additional file 2: Figure 2). The purity of the cold standard sample is > 99.9%, and the purity of two precursors > 99%, identified via HNMR and LC–MS (Additional files 4, 5, 6, 7, 8, 9: Figure 3B–G). The details of the synthetic route were described in the Additional file 14: supplementary text.
Automated radiosynthesis of 18F-deoxy-thiamine
We adopted a two-step synthesis route (Fig. 1). The scheme of automated synthesis was shown in Additional file 1: Figure 1. Reagents were added into supply vials as follows: A1: 1.1 ml eluent (3.08 mg KHCO3, 11 mg Kryptofix 2.2.2, 0.88 mL MeCN, 0.22 mL H2O); A2: 1 ml MeCN; A3: 5 mg precursor (6) in 0.5 ml MeCN; A4: 1 ml MeCN; A5: 0.5 ml MeCN; B1: 0.5 ml H2O. 5 mg precursor (5) powder was also added into reaction vial II beforehand. When the first step synthesis finished, the intermediate product [18F]-compound (7) was transferred from reaction vial I to reaction vial II via distillation. The whole automated synthesis duration was 100 min. The details of synthesis and purification were described in the Additional file 14: supplementary text.
Characterization and quality control of 18F-deoxy-thiamine
Radiochemical yield (RCY, decay-correction to the end of bombardment) and radiochemical concentration (RCC) were measured by the radioactivity calibrator (CRC-55tR, CAPINTEC, INC., USA). 18F-deoxy-thiamine was identified by co-injecting final product with cold standard sample into analytical HPLC. Radiochemical purity (RCP) and specific radioactivity (SA) were calculated by means of the area under curve (AUC) of radio-signals and UV-signals of final product in analytical HPLC, respectively. Bacteria and endotoxin detections were carried out by means of anaerobic/aerobic bacteria media and Limulus reagent gel methods, respectively, according to Chinese Pharmacopoeia.
In vitro stability
18F-deoxy-thiamine solution was stored at room temperature (RT) and injected into analytical HPLC for evaluating RCP and peak shape at 0 h (h), 2 h, 4 h, 6 h, 8 h, and 10 h, respectively, after synthesized.
Thiamine deficiency mouse model
Eight-week-old male C57BL/6 and ICR mice were randomly divided into two groups: TD mouse models (n = 2 for C57BL/6, one died due to anesthesia during micro-PET/CT scanning; n = 3 for ICR) were established by feeding thiamine-deprived diet (Trophic Animal Feed High-tech Co., Ltd., China). Control mice (n = 3 for each strain) were fed the general diet. Twenty-eight days later, all mice received PET/CT scanning.
Micro-PET/CT imaging using 18F-deoxy-thiamine as the tracer was performed in the mice with TD and control mice, as well as in marmosets. The animals were anesthetized by inhaling 1.5–2% of isoflurane in air (1.5 L/min) and received CT scan for acquiring structure image and attenuation correction data. Then, the mice were injected with 7.4–14.8 MBq of 18F-deoxy-thiamine in 0.1 ml volume (diluted by normal saline) through the tail vein. Brain PET imaging was immediately performed and dynamically acquired for 90 min with an energy window of 350–650 KeV and a time window of 3.438 ns. A total of 35 frames were setup: 20 f, 3 s; 4 f, 60 s; 5 f, 300 s; 6 f, 600 s. Dynamic images were reconstructed by OSEM3D/SP-MAP algorithm with two iterations. After scanning, the mice were sacrificed.
The marmosets were injected with 46.3–74.0 MBq of 18F-deoxy-thiamine in 0.5–0.8 ml volume through the femoral vein. Brain PET imaging was immediately scanned and dynamically acquired for 60 min. A total of 18 frames were setup: 6 f, 10 s; 4 f, 60 s; 5 f, 300 s; 6 f, 600 s. The blood samples of the marmosets were taken from femoral vein for measuring the levels of thiamine, TMP, and TDP. The other conditions for marmosets were the same as that for mice.
Regions of interest (ROIs) were drawn manually over the whole brain (for mice and marmosets) and in the left ventricular cavity (for marmosets) based on the PET/CT co-registered images using IRW 4.2 software (Siemens Medical Solutions USA, Inc.). Radioactivity was expressed as standard uptake value (SUV): (ROI radioactivity/ROI volume)/(injected radioactivity/gram of body weight). The time-activity curve (TAC) and AUC (SUV * mins) were also calculated.
The TACs of the marmosets blood (Radioactivity was expressed as SUV) were taken as input functions (IF) [14,15,16] for fitting Patlak plots [17, 18], in order to analyze transfer constants (Ki) of brains in marmosets (IRW 4.2 software). The details of Patlak model were described in the Additional file 14: supplemental text.
Measurement of thiamine, TMP, and TDP in whole blood samples of marmosets
Thiamine, TMP, and TDP levels in whole blood samples were measured using HPLC, based on the established method  with slight modification. Briefly, blood samples were collected using heparin-anticoagulated tubes; 150 ul sample was vibrated for 30 s with equal volume of 5.2% perchloric acid (PCA) added dropwise for deproteinization. Then, the mixture was stored at − 80 °C until assay within 1 month. The mixture was centrifuged at 12,000 rpm for 8 min at 4 °C; the supernatant was pipetted. Thiamine, TMP, and TDP in supernatant were derivatized into thiochromes using potassium ferricyanide and analyzed by gradient elusion with C18 reversed-phase analytical column (250 * 4.6 mm). The derivatives were identified by HPLC fluoroscopy (1100, Agilent Technologies Inc., ex: 367 nm, em: 435 nm). The thiamine, TMP, and TDP levels were quantified using standard samples (Sigma-Aldrich, St. Louis, MO). The analyzers were blinded to samples information.
Studies of pharmacokinetic and metabolic kinetics in liver and kidney of mice
Nine-week-old male ICR mice (n = 5) were dynamically scanned using micro-PET/CT for 60 min. A total of 18 frames were reconstructed: 6 f, 10 s; 4 f, 60 s; 5 f, 300 s; 6 f, 600 s. The scanning conditions were the same as those mentioned above. The ROIs of liver and renal parenchyma as well as left ventricular cavity were manually drawn.
For pharmacokinetic study, the TACs of the blood were fitted. The radioactivity was evaluated as %IA/g (the percentage of injected activity per gram of blood). Pharmacokinetics parameters were counted through the software PKSolver (version 2.0, China Pharmaceutical University) .
For metabolic kinetics study, SUV, TAC, AUC, maximum radioactivity (Cmax), and time to Cmax (Tmax) were calculated. The TACs of the blood (Radioactivity expressed as SUV) were taken as IFs for fitting Logan plots [20, 21], in order to analyze the distribution volumes (VD) of 18F-deoxy-thiamine in liver and kidney, respectively (IRW 4.2 software). The details of Logan model were described in the Additional file 14: supplemental text.
The biodistribution of 18F-deoxy-thiamine was studied in ICR mice (n = 36 in total; 18 males, 9-week-old, 33.5 ± 4.0 g; 18 females, 7-week-old, 27.7 ± 5.0 g). For each mouse, 0.1 ml of 18F-deoxy-thiamine solution (37 MBq/ml) was injected into the tail vein under isoflurane anesthesia. The mice were sacrificed at 5 min, 10 min, 30 min, 1 h, 2 hs, and 4 hs after injection (3 males and 3 females for each time point). The tissues of heart, liver, spleen, lung, kidney, stomach, duodenum, pancreas, femur, muscle (from thigh), artery blood, brain, fat, and gonad (ovary or testicle) were harvested, weighted, and measured for radioactivity by γ-counter. %IA/g was calculated referring to the counts of standard samples.
In vivo stability and the renal excretion rate
After metabolic kinetics study (Heading 9, Materials and Methods section), the mice were stopped to exposure to isoflurane and woke up several mins later. The urine accumulated in the bladder of the mice during the whole anesthetization period would be excreted. Some mice were softly rubbed the lower bowel in order to promote urination as completely as possible. The duration from the injection of 18F-deoxy-thiamine to mouse urination was about 85 min. The urine samples from three ICR mice were collected using syringes and measured in the radioactivity calibrator. Then, 0.1 ml urine for each mouse was added in an Eppendorf tube, vibrated for 30 s with equal volume of PCA added dropwise for deproteinization. After centrifuging at 12,000 rpm for 8 min at 4 °C, the supernatant was filtered and analyzed using HPLC.
For the continuous data, mean ± standard error of mean (SEM) was applied for statistical description. Student's t test was employed to compare the AUC values between TD mice and controls in ICR strain. The Pearson correlation was utilized to analyze the correlation between the cerebral accumulation of 18F-deoxy-thiamine and the levels of blood thiamine, TMP, and TDP in marmosets. Repeated measurement of ANOVA with Tukey’s post hoc was used to analyze the AUC values of 18F-deoxy-thiamine in brain, liver, and kidney in ICR mice. All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences) software (version 22.0; SPSS Inc., Chicago IL).
Characterization and quality control of 18F-deoxy-thiamine
The solution of 18F-deoxy-thiamine was clear and free of any particulate matter. All relevant items of characterization are shown in Table 1. The RCP and SA were 98.28 ± 0.39% and > 55.5 GBq/umol, respectively (Fig. 2). The RCY was 5.17 ± 1.04% (decay-corrected to the end of bombardment), and the RCC was 740–1110 MBq/ml. The bacteria and endotoxin tests were negative. For exploring the expiration time, we tested the stability in vitro. 18F-deoxy-thiamine final product was stable at RT, with the RCP > 95% 6 h, and > 93% 10 h after synthesis (Table 2).
Evaluation of cerebral thiamine metabolism status
The cerebral retention of 18F-deoxy-thiamine was increasing and approached to Cmax at the terminal time of 90 min in the two mice with TD. The SUVsmax of the last frame (80–90 min) were 0.48 (TD 3 mouse), and 0.55 (TD 5 mouse). The AUC values within 90 min were 34.99 (TD 3 mouse) and 42.46 (TD 5 mouse). In contrast, the cerebral retention was stable within 90 min in the three control mice; the SUVsmax were about 0.17 (Ctrl 2 mouse), 0.25 (Ctrl 4 mouse), and 0.3 (Ctrl 1 mouse). The AUC values within 90 min were 14.52 (Ctrl 2 mouse), 20.96 (Ctrl 4 mouse), and 25.67 (Ctrl 1 mouse) (Fig. 3a, b). The mean of AUC values in TD mice was 1.9 times higher than that in control mice (38.73 ± 3.74 vs. 20.38 ± 3.23).
The values of cerebral SUVsmax in three mice with TD were 0.98 at 28th frame (TD 3 mouse, 20–25 min), 0.97 at 30th frame (TD 4 mouse, 30–40 min), and 0.61 at the 33th frame (TD1 mouse, 60–70 min), and then, the SUVs declined slowly. The AUC values within 90 min were 79.28 (TD 3 mouse), 78.75 (TD 4 mouse), and 46.81 (TD 1 mouse), respectively. The SUVsmax of ICR control mice were 0.36 (Ctrl 1 mouse), 0.27 (Ctrl 5 mouse), and 0.18 (Ctrl 3 mouse) within 90 min, respectively. The TACs in control mice were stable, similar to that in the C57BL/6 strain mice. The AUC values within 90 min were 29.58 (Ctrl 1 mouse), 21.14 (Ctrl 5 mouse) and 14.92 (Ctrl 3 mouse), respectively (Fig. 3c, d). The mean of AUC values in TD mice was 3.1 times higher than that in controls (68.28 ± 10.74 vs. 21.88 ± 4.25, P = 0.016).
The retention of 18F-deoxy-thiamine in the cerebrum of three marmosets had been increasing within 60 min (M1, M3, M4) and reached plateau at 16th frame (30–40 min) in M2. The values of SUVmax were between 0.33 and 0.90, and the AUC values within 60 min were between 17.07 and 42.28 (29.33 ± 5.15; Fig. 3e, f). There was a significantly negative correlation between cerebral AUC values within 60 min and TDP levels in whole blood samples (r = − 0.985, p = 0.015, Fig. 3i). No significant correlation was found between the AUC values of 18F-deoxy-thiamine in cerebrum and blood thiamine and TMP levels (Fig. 3g, h). In order to quantitatively evaluate the uptake of 18F-deoxy-thiamine in the cerebrum of marmosets, the Patlak model was utilized to analyze the blood-to-brain transfer rate represented by constant Ki based on the characteristics of metabolic kinetics in the brain. The regression plots were fitted automatically by software from 20 to 60 min. Ki was between 0.0030 and 0.0102 ml/g/min, and significantly correlated with age (r = 0.986, P = 0.014, Fig. 3j, see the fitted Patlak plots in Additional file 10: Figure 4).
Pharmacokinetic study and metabolic kinetics study in liver and kidney of mice
Table 3 shows the pharmacokinetic parameters. Figure 4a shows the TAC of 18F-deoxy-thiamine (radioactivity as IA%/g) within 60 min in the ICR mice blood represented by the ROI in left ventricle. The pharmacokinetic profiles of 18F-deoxy-thiamine fitted a two-compartment open model. The value of AUC0–60 min was 37.313, accounting for 99.77% of the value of AUC0–inf (37.399), which implies that the 60 min observation be sufficient to depict the pharmacokinetic characters. The Tmax was in the first frame (0–10 s) and the Cmax was 18.12 ± 2.20 IA%/g, respectively. The half-life of distribution (t1/2α) and half-life of elimination (t1/2β) were 0.082 and 6.379 min. The volume of distribution (VD1) and clearance rate (CL1) of central compartment were 3.058 g and 2.674 g/min. The VD2 and CL2 of peripheral compartment were 19.308 g and 20.162 g/min. These results revealed that 18F-deoxy-thiamine could be absorbed and eliminated rapidly.
The representative images of dynamic micro-PET/CT whole-body scanning of ICR mice within 60 min are shown in Fig. 5. Initially, 18F-deoxy-thiamine distributed mainly into liver and bladder. Then, the radioactivities in the liver quickly declined, while that in bladder was increasing over time. These results demonstrated that the uptake and elimination of 18F-deoxy-thiamine in vivo were fast and mainly occurred in liver and kidney.
The Tmax in liver was approximately 1 min post-injection. The value of SUVmax was 4.61 ± 0.53. Then, the SUV dropped fast to 3.23 ± 0.50 at approximately 5 min. The radioactivity continued to decline afterward. The SUV was 0.72 ± 0.05 at the terminal time (60 min). The AUC value within 60 min was 79.94 ± 5.43 (Fig. 4b). The Tmax in the kidney was approximately 30 s, and the SUVmax was 18.67 ± 7.04. The SUV dropped fast to 3.29 ± 0.50 in 10 min and continued to drop slowly. At the terminal time (60 min), the SUV dropped to 0.77 ± 0.35. The AUC value was 113.4 ± 15.56 (Fig. 4c). The AUC values of liver and kidney within 60 min were significantly higher than that of whole brain (P < 0.001). Also, the AUC values in kidney were significantly higher than that in liver (P < 0.05, Fig. 4d).
Logan plot was applied to analyze the distribution volume (VD) of liver and kidney based on the characteristics of metabolic kinetics. The regression plots were fitted automatically by software from 10 to 60 min, and VD were 4.573 ± 0.34 ml/g in the liver and 6.17 ± 0.88 ml/g in the kidney (Additional file 11, 12: Figure 5A–E, 6A–E). The results indicated that the “steady-state” of uptake/clearance was reached in the 10th min, and the mean uptake amount of 18F-deoxy-thiamine per gram tissue was equivalent to the amount contained in 4.573 ml (for liver) or 6.17 ml (for kidney) of blood.
In vivo stability and renal excretion rate
Since the -OH group of thiamine is replaced by -18F, 18F-deoxy-thiamine cannot enter the known metabolic pathways of thiamine till 18F decays back to 18O− [22, 23]. The radioactivity in the collected urine was 34.16 ± 3.84% of total injected radioactivity measured by radioactivity calibrator (decay-correction), and no correlation was found between the excreted radioactivity in urine and the injected radioactivity (Additional file 14: Table 1). The RCP of renal excreted 18F-deoxy-thiamine was 94.53 ± 0.81% determined by HPLC. In addition, an unknown trace substance (3.30 ± 0.60% in RCP) was found ahead of 18F-deoxy-thiamine, which could not be 18F− ions according to its retention time and shape (Fig. 6). The percentage of intact tracer was 96.63%. These results indicated that about one-third of 18F-deoxy-thiamine was excreted by kidney and that 18F-deoxy-thiamine was stable within 85 min in vivo.
As a derivative of an essential vitamin, 18F-deoxy-thiamine distributed widely in vivo. In most of the organs and tissues of ICR mice, the Cmax of 18F-deoxy-thiamine achieved between 5 and 15 min, then 18F-deoxy-thiamine was cleared rapidly, and the accumulation was very low in these organs and tissues till 4 h after injection (Fig. 7, Additional file 14: Table 2). The muscular radioactivity in female ICR mice began to decline 5 min after injection, differentiating from that in male ICR mice, in which the radioactivity increased within 60 min, then declined rapidly.
Consistent with the results of PET/CT scanning, the biodistributions of liver and kidney were higher than that in the other organs investigated. The biodistributions of 18F-deoxy-thiamine in brain, fat, and gonad were less than those in other organs or tissues observed in this study. Interestingly, the level of 18F-deoxy-thiamine in the ovary was higher than that in the testicle, indicating the difference in 18F-deoxy-thiamine metabolism between male and female gonads.
The levels of thiamine and its phosphate esters decline in the brains of mice with TD . Our current study showed the retention of 18F-deoxy-thiamine was higher in the cerebra of two strains mice with TD as compared with that in control mice (Fig. 3a–d). The results indicate that the enhanced accumulation of 18F-deoxy-thiamine in the brain could reflect the status of cerebral thiamine deficiency of the mice. It may be due to the fact that brain elevates the uptake efficiency of thiamine from periphery blood in order to meet the demands of high rate of glucose metabolism as well as other thiamine-dependent physiological activities under the condition of thiamine deficiency. TDP accounts for 90% of total thiamine in the body . We observed that the level of 18F-deoxy-thiamine in the brain significantly negatively correlated with blood TDP levels in marmosets (Fig. 3i). In addition, the blood-to-brain transfer rate as represented by Ki was significantly positively correlated with the age of marmosets (Fig. 3j), suggesting that the reserve of thiamine in marmosets declines with age. The result is consistent with our previous observation in the non-demented elderly . Of course, this result should be further validated by expanding the sample size in future studies.
The previous study has showed that TDP reduction contributes to cerebral glucose hypometabolism of AD, and the concentration of blood TDP was positively correlated with the level of cerebral glucose metabolism in AD patients . Cerebral glucose metabolism is extremely high . Under normal circumstances, the brain glucose concentration is kept constant at the millimole concentration and cerebral metabolic rate of glucose (CMRGlu) reaches 0.2–0.3 umol/g/min . It may lead to the possibility that slight alteration of brain glucose metabolism under some pathological conditions is difficult to be detected by PET with [18F]-fluorodeoxyglucose (FDG-PET). In this study, the SUVs of 18F-deoxy-thiamine in the brains of control mice and marmosets were less than 0.4 and 0.9, respectively (Fig. 3a, c, e). It is much lower than that of FDG in the range of 1–2 in the brains of mice . The results imply that PET with 18F-deoxy-thiamine may be more sensitive than FDG-PET for evaluation of mild brain hypometabolism status. The advantages and disadvantages of these two methods for detecting brain metabolic status should be further investigated in future studies.
In both genders of ICR mice, kidney, liver, and pancreas exhibit high accumulation level of 18F-deoxy-thiamine, while brain, muscle, fat, and gonad show low accumulation concentration (Fig. 7; Additional file 14: Table 2, 3). These results are consistent with previous reports on the biodistributions of thiamine and its phosphate esters [30,31,32]. Besides, we found that 3.37% of 18F-deoxy-thiamine in urine was metabolized to more polar compounds after 85 min in vivo process (Fig. 6). To our knowledge, the –OH group is the active site for thiamine converting into bioactive TDP in vivo [22, 23]. Thus, before –18F decays back to stable isotope –18O, 18F-deoxy-thiamine could not enter the known metabolic routes. The presence of this 3.37% compounds implied other unknown metabolic routes might exist. 18F-deoxy-thiamine could help for further exploration on the metabolism and biodistribution of thiamine.
Stability is important for PET tracer. 18F-deoxy-thiamine was stable at RT. The RCP was > 95% 6 h, and > 93% 10 h after synthesis, which means no significant radiolysis effect exists in vitro (Table 2) . In addition, no 18F-deflourination of 18F-deoxy-thiamine in vivo was observed based on the phenomenon that the accumulation of radioactivity signal in bone was decreasing over time  (Fig. 7b, e). Also, the prototype form of 18F-deoxy-thiamine excreted in urine reached 96.63% within 85 min after vein injection (Fig. 6). These results demonstrated that 18F-deoxy-thiamine was highly stable both in vitro and in vivo.
Pharmacokinetic and metabolic kinetics studies as well as biodistribution study indicated that the uptake and clearance of 18F-deoxy-thiamine in vivo were fast, which is another important requirement. The t1/2β was 6.379 min; CL1 and CL2 were 2.674 g/min and 20.162 g/min, respectively (Table 3). The values of Cmax in various tissues and organs of ICR mice reached within 15 min (except for muscle of males, reached within 1 h), and the accumulation of 18F-deoxy-thiamine was very low in these tissues and organs till 4 h after injection (Fig. 7, Additional file 14: Table 2 and 3). Besides, at least one-third of 18F-deoxy-thiamine was excreted through kidney 85 min after injection. (A small amount of urine may be retained in bladder and not be collected.) See Additional file 14: supplementary Table 1.
Graphical analysis technique has been extensively applied in the analyses of nuclear medicine imaging data. It is especially suitable for pharmacokinetic studies of novel tracers before the compartmental models are fully described, because it is independent of any specific model configuration . We analyzed the important kinetic parameters Ki and VD in the brain of marmosets and in the liver and kidney of ICR mice employing Patlak and Logan plots, respectively, based on the characteristics of TACs in these organs (Figs. 3e, 4b, c). The VD in the kidney and liver of ICR mice were 6.17 ± 0.88 ml/g and 4.573 ± 0.34 ml/g, respectively. The results showed that the uptake and clearance of 18F-deoxy-thiamine in vivo were fast.
Thiamine consists of a pyrimidine ring with an electronegative amidogen and a thiazole ring. The structural complexity determines the difficulty of artificially synthesizing and modifying thiamine. Since the first synthesis route was reported in 1937 , only a few studies on thiamine synthesis and modification have been published [35,36,37]. Recently, Doi et al.  synthesized radio-labeled thiamine with 11C and conducted heart imaging study in rats . Although 11C-thiamine possesses the same molecular structure as thiamine itself, the short half-life of 11C (20.4 min) limits its application. Also, 11C-thiamine would be phosphorylated to 11C-TDP fast via the –OH group in vivo , which complicates the interpretation of the radio-signal. Here, 18F-deoxy-thiamine was successfully synthesized by a two-step route, in which –OH group of thiamine replaced by –18F (Fig. 1). Although the RCY was not high enough, the RCP, SA, and RCC were high (Table 1). The bacteria and endotoxin tests were negative. These results indicated that 18F-deoxy-thiamine was safe and suitable for in vivo studies.
The most difficult part in our two-step route is the isolation and purification of the intermediate product 18F-compound (7). Though we have tried various solid phase extractions as well as preparative HPLC, either the isolation failed or the process became too complicated to be automated. The molecule of 4-methyl-5(beta-hydroxyethyl)-thiazole is solid, and its boiling point is 135 °C under vacuum . Once –OH is changed to –F, however, this compound becomes oil and volatile at RT. We speculated that it was because the H bond connecting H and N was broken (Additional file 13: Figure 7). By distillation, we successfully isolated 18F-compound (7) and realized the automation of the radiosynthesis route.
In this study, we synthesized a novel PET tracer of 18F-deoxy-thiamine and established its automated synthesis route. Further, 18F-deoxy-thiamine was stable in vitro and in vivo, and possessed ideal characteristics of metabolic kinetics. The PET with 18F-deoxy-thiamine could evaluate the status of cerebral thiamine metabolism and might be more suitable for evaluating cerebral energy metabolism than FDG-PET due to the low abundance of cerebral thiamine metabolism. However, the sample size of marmosets in this study was not large enough, and we lack of TD model of marmosets to further investigate thiamine metabolism in non-human primates. This study laid the foundation for further studies on diseases related to thiamine dysmetabolism.
Availability of data and materials
The datasets used in the current study are available from the corresponding author on reasonable request.
Pentose phosphate pathway
Thin layer chromatography
Parts per million
Ml per minute
Area under curve
Region of interest
Standard uptake value
- K i :
Standard error of mean
Talwar D, Davidson H, Cooney J, St JD. Vitamin B(1) status assessed by direct measurement of thiamin pyrophosphate in erythrocytes or whole blood by HPLC: comparison with erythrocyte transketolase activation assay. Clin Chem. 2000;46:704–10.
Dhir S, Tarasenko M, Napoli E, Giulivi C. Neurological, psychiatric, and biochemical aspects of thiamine deficiency in children and adults. Front Psychiatry. 2019;10:207.
Hiffler L, Rakotoambinina B, Lafferty N, Martinez GD. Thiamine deficiency in tropical pediatrics: new insights into a neglected but vital metabolic challenge. Front Nutr. 2016;3:16.
Pan X, Fei G, Lu J, Jin L, Pan S, Chen Z, et al. Measurement of blood thiamine metabolites for Alzheimer’s disease diagnosis. EBio Med. 2016;3:155–62.
Bouzier-Sore AK, Voisin P, Bouchaud V, Bezancon E, Franconi JM, Pellerin L. Competition between glucose and lactate as oxidative energy substrates in both neurons and astrocytes: a comparative NMR study. Eur J Neurosci. 2006;24:1687–94.
Butterworth RF, Kril JJ, Harper CG. Thiamine-dependent enzyme changes in the brains of alcoholics: relationship to the Wernicke-Korsakoff syndrome. Alcohol Clin Exp Res. 1993;17:1084–8.
Martin PR, Singleton CK, Hiller-Sturmhofel S. The role of thiamine deficiency in alcoholic brain disease. Alcohol Res Health. 2003;27:134–42.
Kril JJ, Harper CG. Neuroanatomy and neuropathology associated with Korsakoff’s syndrome. Neuropsychol Rev. 2012;22:72–80.
Opdenakker G, Gelin G, De Surgeloose D, Palmers Y. Wernicke encephalopathy: MR findings in two patients. Eur Radiol. 1999;9:1620–4.
Kornreich L, Bron-Harlev E, Hoffmann C, Schwarz M, Konen O, Schoenfeld T, et al. Thiamine deficiency in infants: MR findings in the brain. AJNR Am J Neuroradiol. 2005;26:1668–74.
Jankowska-Kulawy A, Bielarczyk H, Pawelczyk T, Wroblewska M, Szutowicz A. Acetyl-CoA deficit in brain mitochondria in experimental thiamine deficiency encephalopathy. Neurochem Int. 2010;57:851–6.
Gibson GE, Blass JP, Beal MF, Bunik V. The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. Mol Neurobiol. 2005;31:43–63.
Cline JK, Williams RR, Finkelstein J. Studies of crystalline vitamin B1. XVII. Synthesis of vitamin B1. J Am Chem Soc. 1937;59:1052–4.
Laforest R, Sharp TL, Engelbach JA, Fettig NM, Herrero P, Kim J, et al. Measurement of input functions in rodents: challenges and solutions. Nucl Med Biol. 2005;32:679–85.
Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, et al. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther. 2006;316:647–53.
Wanek T, Traxl A, Bankstahl JP, Bankstahl M, Sauberer M, Langer O, et al. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier. Nucl Med Biol. 2015;42:585–9.
Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7.
Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1985;5:584–90.
Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306–14.
Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740–7.
Logan J. A review of graphical methods for tracer studies and strategies to reduce bias. Nucl Med Biol. 2003;30:833–44.
Bettendorff L, Wins P. Thiamin diphosphate in biological chemistry: new aspects of thiamin metabolism, especially triphosphate derivatives acting other than as cofactors. FEBS J. 2009;276:2917–25.
Manzetti S, Zhang J, van der Spoel D. Thiamin function, metabolism, uptake, and transport. Biochemistry. 2014;53:821–35.
Sang S, Pan X, Chen Z, Zeng F, Pan S, Liu H, et al. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer’s disease, whereas amyloid deposition does not. Alzheimers Res Ther. 2018;10:26.
Lu J, Frank EL. Rapid HPLC measurement of thiamine and its phosphate esters in whole blood. Clin Chem. 2008;54:901–6.
Lu J, Pan X, Fei G, Wang C, Zhao L, Sang S, et al. Correlation of thiamine metabolite levels with cognitive function in the non-demented elderly. Neurosci Bull. 2015;31:676–84.
de Castro IP, Martins LM, Tufi R. Mitochondrial quality control and neurological disease: an emerging connection. Expert Rev Mol Med. 2010;12:e12.
Dienel GA. Brain glucose metabolism: integration of energetics with function. Physiol Rev. 2019;99:949–1045.
Wong KP, Sha W, Zhang X, Huang SC. Effects of administration route, dietary condition, and blood glucose level on kinetics and uptake of 18F-FDG in mice. J Nucl Med. 2011;52:800–7.
Klooster A, Larkin JR, Wiersema-Buist J, Gans RO, Thornalley PJ, Navis G, et al. Are brain and heart tissue prone to the development of thiamine deficiency? Alcohol. 2013;47:215–21.
Gangolf M, Czerniecki J, Radermecker M, Detry O, Nisolle M, Jouan C, et al. Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells. PLoS ONE. 2010;5:e13616.
Hilbig R, Rahmann H. Comparative autoradiographic investigations on the tissue distribution of benfotiamine versus thiamine in mice. Arzneimittelforschung. 1998;48:461–8.
Jacobson MS, Dankwart HR, Mahoney DW. Radiolysis of 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) and the role of ethanol and radioactive concentration. Appl Radiat Isot. 2009;67:990–5.
Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171–84.
Archer S, Perianayagam C. An attempt to apply lethal synthesis to the design of chemotherapeutic agents. Fluorinated 5 beta-(hydroxyethyl)-4-methylthiazoles. J Med Chem. 1979;22:306–9.
Lowe G, Potter BVL. Bacteriostatic activity of fluoro-analogues of 5-(2-hydroxyethyl)-4-methylthiazole, a metabolic intermediate in the biosynthesis of thiamine. J Chem Soc Perkin Trans. 1980;1:2026–8.
Doi H, Mawatari A, Kanazawa M, Nozaki S, Nomura Y, Kitayoshi T, et al. Synthesis of (11)C-labeled thiamine and fursultiamine for in vivo molecular imaging of vitamin B1 and its prodrug using positron emission tomography. J Org Chem. 2015;80:6250–8.
Nozaki S, Mawatari A, Nakatani Y, Hayashinaka E, Wada Y, Nomura Y, et al. PET imaging analysis of vitamin B1 kinetics with [(11)C]thiamine and its derivative [(11)C]thiamine tetrahydrofurfuryl disulfide in rats. Mol Imaging Biol. 2018;20:1001–7.
Amos WJ, Neal RA. Isolation and identification of 3-(2’-methyl-4’-amino-5’-pyrimidylmethyl)-4-methylthiazole-5-acetic acid (thiamine acetic acid) and 2-methyl-4-amino-5-formylaminomethylpyrimidine as metabolites of thiamine in the rat. J Biol Chem. 1970;245:5643–8.
We thank Profess Fengling Qing, Profess Xiuhua Xu, and Doctor Zenghao Chen for their assistance in synthesis routes.
This study was supported by grants from the National Key Research and Development Program Foundation of China (2016YFC1306403) to Chunjiu Zhong, Science and Technology Commission of Shanghai Municipality (20ZR1411300) to Changpeng Wang, National Natural Science Foundation of China (91332201) to Chunjiu Zhong, and Zhongshan Hospital Science Foundation (2018ZSQN28) to Changpeng Wang.
Ethical approval and consent to participate
All animal care and experimental procedures were carried out according to the guidelines of the Animal Care Committee of Fudan University. This study was approved by Medical Experimental Animal Administrative Committee of Fudan University, and the committee on medical ethics of Zhongshan Hospital, Fudan University.
Consent for publication
Chunjiu Zhong holds shares of Shanghai Rixin Biotech Co., Ltd., which focuses on the development of new drugs against Alzheimer’s disease. The other authors declare that he/she has no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The scheme of radio-synthesis using an automated module.
The synthesis route of cold standard sample of 18F-deoxy-thiamine as well as precursors (5) and (6).
A: The TLC analyses results of intermediate products in the synthesis route of cold standard sample of 18F-deoxy-thiamine.
B: HNMR result of precursor 5.
C: LC-MS result of precursor 5, the purity has been highlighted.
D: HNMR result of precursor 6.
E: LC-MS result of precursor 6, the purity has been highlighted.
F: HNMR result of cold standard sample of 18F-deoxy-thiamine.
G: LC-MS result of cold standard sample of 18F-deoxy-thiamine, the purity has been highlighted.
Blood-to-brain transfer rate constant Ki of 18F-deoxy-thiamine analyzed by Patlak plot in marmosets. A: M1, 3.1 years old. B: M2, 3.5 years old. C: M3, 5.4 years old. D: M4, 10.8 years old. The unit of Ki is ml/g/min.
Distribution volume (VD) of 18F-deoxy-thiamine in liver analyzed by Logan plot in ICR mice. A–E: Each figure is for one of five ICR mice, respectively. The unit of VD is ml/g.
Distribution volume (VD) of 18F-deoxy-thiamine in kidney analyzed by Logan plot in ICR mice. A–E: Each figure is for one of five ICR mice, respectively. The unit of VD is ml/g.
The H bond connecting H and N of 4-methyl-5(beta-hydroxyethyl)-thiazole is broken.
About this article
Cite this article
Wang, C., Zhang, S., Zou, Y. et al. A novel PET tracer 18F-deoxy-thiamine: synthesis, metabolic kinetics, and evaluation on cerebral thiamine metabolism status. EJNMMI Res 10, 126 (2020). https://doi.org/10.1186/s13550-020-00710-5
- Positron emission tomography